title: Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab.
authors.affiliation: a GlaxoSmithKline , Collegeville , PA , USA ;
authors.forename: Thierry J
authors.initials: TJ
authors.lastname: Horner
authors.affiliation: b Novartis Pharmaceuticals, Oncology Clinical Pharmacology , Morrisville , NC , USA ;
authors.forename: Vanessa C
authors.initials: VC
authors.lastname: Williams
authors.affiliation: b Novartis Pharmaceuticals, Oncology Clinical Pharmacology , Morrisville , NC , USA ;
authors.forename: Patricia
authors.initials: P
authors.lastname: Giampietro
authors.affiliation: c Pfizer , Collegeville , PA , USA ;
authors.forename: Philip A
authors.initials: PA
authors.lastname: Witman
authors.affiliation: d Janssen Pharmaceuticals , Horsham , PA , USA.
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Lin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000532:radiotherapy*; D009190:Myelodysplastic Syndromes / Q000378:metabolism / Q000532:radiotherapy*; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000970:Antineoplastic Agents; C119496:tositumomab I-131